NR-V04 exhibits antitumor effects in several tumor models. (A–F) Tumor-bearing mice were treated with 1.8 mg/kg NR-V04 or vehicle via i.p. injection on day 7 when tumors were palpable. The treatment was repeated every 4 days until the tumors reached the endpoint size of 2 cm in diameter. (A) NR-V04 inhibited MC38 colon adenocarcinoma growth. P < 0.0001, four mice per group, two experiments. (B) NR-V04 inhibited Yummer1.7 melanoma growth. P < 0.0001, four mice per group, two experiments. (C) NR-V04 inhibited B16F10 melanoma growth. P < 0.0001, five mice per group, two experiments. (D) NR-V04 failed to inhibit B16F10 melanoma growth in NR4A1^−/− mice. P = 0.7139, five mice per group in one experiment. (E) NR-V04 failed to inhibit MC38 colon adenocarcinoma growth in NSG mice. P = 0.1293, five mice per group in one experiment. (F) NR-V04 failed to inhibit B16F10 melanoma in NSG mice. P = 0.1801, five mice per group in one experiment. Two-way ANOVA was performed for all tumor growth curves with P values indicated.